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1 Introduction
Amaranth is a pseudo cereal native to Andean countries and 
has been consumed in that region since the pre-Columbian era. 
Interest in its widespread consumption for human nutrition has 
grown recently due to favorable reports of amaranth nutritive 
value and health benefits. In addition to its promising nutritional 
qualities, amaranth may also be valuable for celiac patients (TOSI; 
CIAPPINI; MASCIARELLI,1996), diabetic (CHATURVEDI 
et al., 1997), hypercholesterolemic subjects (MAIER; TURNER; 
LUPTON, 2000) and coronary heart disease and hypertension 
patients (MARTIROSyAN et al., 2007). Among several possible 
processing methods, extrusion is the most interesting from the 
nutritional and economical point of view because it produces a 
stable product with all nutritive aspects preserved or enhanced 
(BRESSANI; SANCHEZ-MARROqUIN; MORALES, 1992; 
MENDOZA; BRESSANI, 1987).
Extrusion cooking has been optimized for the production 
of amaranth snacks that presented a high acceptability as 
compared with commercial brands (CHÁVEZ-JÁUREGUI; 
SILVA; ARÊAS, 2000; CHÁVEZ-JÁUREGUI et al., 2003).
The nutritional evaluation of these snacks showed that they 
exhibit a high nutritional value in terms of protein biological 
value, bioavailability of minerals, and high content of fiber 
(CHÁVEZ-JÁUREGUI; SILVA; ARÊAS, 2000; FERREIRA; 
ARÊAS, 2004). Amaranth’s cholesterol-lowering properties 
have been investigated in animal models and humans using 
differently processed amaranth of various species and cultivars 
(BERGER et al., 2003; CHATURVEDI; SAROJINI; DEVI, 1993; 
DANZ; LUPTON, 1992; GRAJETA, 1999; MAIER; TURNER; 
LUPTON, 2000). In an experiment with hypercholesterolemic 
Resumo
Avaliamos os efeitos de snacks feitos com amaranto desengordurado (Amaranthus caudatus L.) no metabolismo lipídico de pacientes 
com hipercolesterolemia moderada. O ensaio clínico contou com vinte e dois voluntários [30–65 anos, 11 homens, com colesterol total 
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entre o amaranto e o placebo no colesterol total, LDL–c e TG, cujos valores foram, respectivamente, −8,4 e −5,7% (p = 0,17); −12,3 e −9,7% 
(p = 0,41) e −0,6 e −7,3% (p = 0,47). Entretanto, o consumo de snacks de amaranto reduziu significativamente o HDL–c: −15,2 vs. −4% 
(p = 0,03). Concluímos que o consumo de 50 g de amaranto extrusado por 60 dias não foi suficiente para reduzir significativamente LDL−c 
em pacientes com hipercolesterolemia moderada; além disso, observou-se significativa redução de HDL-c. Estudos com maior número de 
participantes e maior quantidade de amaranto são necessários para se testarem os seus efeitos no metabolismo humano.
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Abstract
We evaluated the effects of defatted amaranth (Amaranthus caudatus L.) snacks on plasma lipids in moderate hypercholesterolemic patients. 
Twenty-two subjects [30−65 years old), 11 males, with total cholesterol (TC) ≥ 240 mg.dL–1, low-density cholesterol (LDL−c) 160−190 mg.dL–1 
and plasma triglycerides (TG) < 400 mg.dL–1] were randomized in a double blind clinical trial to receive an amaranth snack (50 g/day) 
or equivalent corn snack (placebo) for 2 months. There were no differences between amaranth and placebo on TC and LDL−c, and TG 
respectively: −8.4 and −5.7% (p = 0.17); −12.3 and −9.7% (p = 0.41) and −0.6 and −7.3% (p = 0.47). However, amaranth snacks significantly 
reduced high-density cholesterol (HDL−c): −15.2 vs. −4% (p = 0.03). In conclusion, the intake of 50 g of extruded amaranth daily during 60 
days did not significantly reduce LDL−c in moderate hypercholesterolemic subjects; furthermore there was a significant reduction in HDL−c. 
Studies with greater number of subjects and greater quantity of this food are necessary to test the effects of amaranth on lipid metabolism 
in humans.
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snacks were flavored with pizza or bacon, 15% canola oil, and 
0.9% of salt and they were packed in bags without labeling. 
In order to retain the flavor, canola oil was chosen because it 
does not induce hypercholesterolemia as compared to partially 
hydrogenated vegetable fat.
2.3 Proximate analysis
The proximate composition of the amaranth and corn 
snacks was determined by conventional methods for protein 
and ash, as described by AOAC (ASSOCIATION..., 1990). 
Lipid extraction was performed using the dry column method 
in accordance with Marmer and Maxwell (1981). Carbohydrate 
was estimated by difference from 100.
2.4 Fatty acid composition
Ten grams of milled snacks were used to analyze the 
fatty acid composition, and an aliquot containing 50 mg of 
lipid obtained using the dry column method was extracted 
as described previously (MARMER; MAxWELL 1981). The 
fatty acid esterification was carried out in accordance with the 
method developed by Hartman and Lago (1973). The fatty acid 
methyl esters were analyzed by gas chromatography using a 
Chrompack CP9002 and a fused silica capillary column (CP−Sil 
88; 50 m × 0.25 mm I.D. 0.20 µm film).
2.5 Clinical analyses
Blood samples were collected after 12-hours fasting for the 
determination of plasma lipids. Commercial enzymatic methods 
were used for total and HDL−cholesterol and triglycerides. The 
LDL-c levels were determined through the Friedewald, Fredrick, 
and Levi (1972) equation for TG lower than 400.0 mg.dL–1: 
[LDL-cholesterol = total cholesterol- (HDL−cholesterol+triglyc
eride/5)]. The content of very low-density cholesterol (VLDL-c) 
was evaluated by the formulae: VLDL-cholesterol = TG/5 for 
TG lower than 400.0 mg.dL–1. Data are expressed as mean ± 
Standard Deviation (SD).
2.6 Statistical analyses
The statistical analyses were performed using the Stata 
version 7 (Stata Corp, College Station, Tx). The comparison 
of nonparametric data was performed by the Wilcoxon signed 
rank test. The level of significance was set at p < 0.05. 
3 Results and discussion
The proximate analysis and fatty acid composition of the 
amaranth snack are shown in Table 1. The snack contained 
rabbits, Plate and Arêas (2002) observed a reduction of 50 
and 18% of total cholesterol when the animals were fed diets 
with extruded amaranth and amaranth oil. Further study 
demonstrated that protein is the major responsible for this 
hypocholesterolemic effect (MENDONçA et al., 2009). This fact 
opened the possibility of using whole amaranth or its protein 
as a functional food for dislipidemia treatment and possible 
atherosclerosis prevention. However, the effect of amaranth 
consumption in plasma lipids has not been clearly shown in 
humans. The purpose of this study was to evaluate the effects 
of extruded amaranth snack on plasma lipids of moderate 
hypercholesterolemic subjects.
2 Materials and methods
2.1 Clinical trial
Study subjects were recruited among the patients of the 
Heart Institute (InCor), University of São Paulo Medical 
School Hospital, Lipid Clinic Section. Twenty two moderate 
hypercholesterolemic patients (11 males) aged 30−65 years, 
with TC ≥ 240 mg.dL–1 and LDL−c levels 160−190 mg.dL–1 
and TG < 400 mg.dL–1 were included. The exclusion criteria 
were previous history of diabetes, thyroid, liver, and coronary 
artery diseases, as well as use of lipid lowering drugs in the last 
6 weeks and smoking. The subjects followed a step I American 
Heart Association diet for at least 3 months. The study was 
approved by the Ethical Committee of the InCor (Instituto do 
Coração - SP, Brazil – a heart disease treatment center), and a 
written informed consent was obtained. The subjects’ baseline 
data are shown in Table 2. The subjects were randomized in a 
double blind fashion to receive either an amaranth (50 g/day) 
or a corn snack (placebo) for 2 months.
2.2 Snack production
Amaranth (Amaranthus caudatus L.) CAC−43A, Oscar 
Blanco variety was provided by the germ plasma bank of the 
“Centro de Investigación en Cultivos Andinos (CICA)” of the 
National University of San Antonio Abad del Cusco – Peru. The 
grain was milled in stainless steel knife mill (Mod. Termomatic, 
Marconi - SP, Brazil) and defatted with n-hexane in soxhlet 
apparatus to a lipid concentration of 0.16%. The amaranth 
snacks developed in this study were extruded as described by 
Chávez-Jáuregui, Silva and Arêas (2000). The conditions were: 
a 20 mm laboratory single screw extruder with 20:1 L/D ratio, 
screw of 4:1compression ratio, screw speed 200 rpm, feed 
moisture 15%, feed material at 70 g/minute, temperature at the 
metering zone 150 °C, and die of 3 mm. The expansion ratio 
of the product was typically 3.5 to 4. The amaranth and corn 
Table 1. Proximate composition of amaranth and corn snacks (g.100 g–1) and percentage of fatty acid composition.
Material Protein Lipids Carbohydrate Ash Kcal
Amaranth 14.18 14.10 67.00 4.72 451.62
Corn 6.33 14.80 76.60 2.31 464.92
Percentage of fatty acid composition
C16:1 C18:0 C18:1 C18:2 C18:3 C23:0 C20:5 C24:6
Amaranth snack 13.04 2.42 36.50 28.62 4.59 1.57 11.67 1.59
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25 g protein/day must be tested in human subjects in order to 
detect any possible effect of this food on total and LDL-c. One 
important finding of our study was the significant reduction 
in HDL-c plasma levels with amaranth consumption. This 
implicates in possible deleterious consequences since low HDL-c 
is an independent risk factor for atherosclerosis. Similarly, lower 
HDL-c levels were also found in amaranth fed rabbits (PLATE; 
ARÊAS, 2002), and it has not been clearly understood yet. 
HDL-c reduction in both rabbits and humans could be explained 
by several mechanisms. A reduced methionine/lysine ratio is 
observed in amaranth, similarly to what is observed in soy. The 
low methionine/lysine ratio observed in soy has been associated 
with the reduction in HDL-c secretion in rats (MORITA et al., 
1997). This reduction might be also related to the possible 
effects of amaranth protein reducing cholesterol levels and to 
the higher sensitivity of HDL-c to this reduction. However, the 
exact mechanism must be further elucidated.
4 Conclusion
In conclusion, the consumption of 50 g of extruded amaranth 
daily (ca 7 g of protein/day) for 60 days did not significantly 
reduce total or LDL-c in moderate hypercholesterolemic 
subjects. It was observed, however, a significant reduction 
in HDL-c following this consumption. A reduction in total 
cholesterol in the subjects that consumed amaranth snack for 
60 days was also observed although this reduction was not 
significant (p = 0.17). Further studies with greater number of 
subjects and higher intake of this food are necessary to test the 
effects of amaranth on lipid metabolism in humans. 
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